In vivo Nanosensors for Therapeutics (IVN:Tx) DARPA-BAA-12-34

DUE:  18 September 2012


SCOPE:   The specific objective of the In vivo Nanoplatforms for Therapeutics (IVN:Tx) thrust of the In vivo Nanoplatforms (IVN) program is to develop novel, biocompatible nanotherapeutic platforms with sequence, specificity, and function that can be programmed “on-the-fly” to treat military-relevant diseases. IVN:Tx will develop new methods to increase nanotherapeutic safety that minimize dose required for clinically relevant efficacy, limit off-target effects, and limit immunogenicity. IVN:Tx will also develop new methods to increase nanotherapeutic effectiveness by targeting delivery to specific tissues and/or uptake by cells of interest, increasing bioavailability, knocking down medically relevant molecular target(s), and increasing resistance to degradation. Successful nanotherapeutic platforms should enable treatment of military-relevant diseases such as infections caused by multi-drug resistant organisms and conditions due to traumatic brain injury.


Timothy Broderick, email:  [email protected]

Please see URL for details:

Innovation Fast Track

EXCLUSIVE TO CENTER MEMBERS: Log in to explore your Innovation Fast Track, an online portal that gives you one-stop access to center researchers, funding opportunities, exclusive events and more.

Learn More
Student Central

Students, get connected with Industry Partners, find out about research and volunteer opportunities within ALERT, or get advice on how to best showcase your work at Student Central.

Learn More
The Partnership

ALERT is led by Northeastern University (NEU) and includes three key academic strategic partners: Boston University, Purdue University, and University of Rhode Island (URI).

Learn More